Company Profile
PaxMedica Stock Price, News & Catalysts
- Ticker:
- PXMD
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.00 USD (+14.29%)
Close
Last updated: August 20, 2026
—
Market cap
Why the stock is moving
Current closing-price context is not available for PXMD.
Company overview
Business overview
PaxMedica is a biotechnology company focused on neurodevelopmental disorders and other high-unmet-need conditions. Its story is centered on using a small pipeline to address difficult patient populations.
Geographic Base and Sector Classification
PaxMedica is headquartered in the United States and listed on NASDAQ. It sits in small-cap biotechnology.
Business Model Characteristics
The company depends on clinical progress, capital efficiency, and the ability to keep a narrow pipeline moving. Investors usually watch early data and whether the company can sharpen its thesis.
Position Within the Biotechnology Landscape
PaxMedica occupies a speculative small-cap biotech niche. It is catalyst-sensitive because the company is still proving its therapeutic relevance.
Future catalysts
- PaxMedica’s catalysts are PAX-101 and the neurodevelopment / rare-disease programs, where any update can materially change sentiment. The stock remains highly data-dependent.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PaxMedica (PXMD)?
PaxMedica (PXMD) most recently closed at 0.00 USD, a +14.29% move versus the previous session.
What does PaxMedica do?
PaxMedica is a biotechnology company focused on neurodevelopmental disorders and other high-unmet-need conditions. Its story is centered on using a small pipeline to address difficult patient populations.
On which exchange is PXMD stock listed?
PaxMedica (PXMD) is associated with NASDAQ, United States, Biopharma.
What is PAX-101?
PaxMedica’s catalysts are PAX-101 and the neurodevelopment / rare-disease programs, where any update can materially change sentiment.
Which conditions is PaxMedica targeting with PAX-101?
PaxMedica’s catalysts are PAX-101 and the neurodevelopment / rare-disease programs, where any update can materially change sentiment.
How does PaxMedica describe recent progress with PAX-101?
PaxMedica’s catalysts are PAX-101 and the neurodevelopment / rare-disease programs, where any update can materially change sentiment.
What is PaxMedica?
PaxMedica is a biotechnology company focused on neurodevelopmental disorders and other high-unmet-need conditions.
What should investors watch for with PaxMedica?
PaxMedica’s catalysts are PAX-101 and the neurodevelopment / rare-disease programs, where any update can materially change sentiment.